title: Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes.
abstract: Monocyte chemotactic protein 1 (MCP-1)-directed transendothelial migration of monocytes plays a key role in the early development of atherosclerosis. Migration of monocytes requires degradation of extracellular matrices, a process that involves matrix metalloproteinases (MMP) and tissue inhibitors of MMPs (TIMP). Recent studies suggest that the alpha1-adrenergic receptor antagonist doxazosin (Dox) might have antiatherosclerotic effects, although the underlying mechanisms are poorly understood. The purpose of the present study was to determine the effects of Dox on MCP-1-directed monocyte migration, MMP-9 activity, and TIMP-1 expression. MCP-1 (50 ng/ml) stimulated migration of human peripheral blood monocytes (HPBM) 2.7+/-0.42-fold and THP-1 human monocytes 5.9+/-0.83-fold compared with unstimulated control. Dox inhibited MCP-1-induced migration in a dose-dependent manner, with a maximal reduction at 10 microM of 69.5+/-5.9% in HPBM and 72.2+/-3.2% in THP-1 cells. Dox blocked migration even after pretreatment with phenoxybenzamine, an irreversible alpha1-adrenergic receptor antagonist (HPBM: phenoxybenzamine 1 microM + Dox 10 microM, 71.9+/-2.2% inhibition; THP-1 cells: phenoxybenzamine 1 microM + Dox 10 microM: 78+/-7.7% inhibition), suggesting that the antimigratory activity of Dox is mediated through a novel mechanism unrelated to its blocking of the alpha1-adrenergic receptor. Dox (10 microM) inhibited MMP-9 activity by 67.6+/-10.5%, whereas MMP-9 protein levels were not affected. Also, Dox increased PMA-induced-tissue inhibitor of MMPs-1 (TIMP-1) expression by 134.4+/-6.6%. Dox 10 microM. The present study demonstrates a potential novel antiatherosclerotic action of Dox by blocking MCP-1-directed monocyte migration, which might be partly mediated by inhibition of MMP-9 activity.
authors.affiliation: University of California, Los Angeles, School of Medicine, Division of Endocrinology, Diabetes and Hypertension, 90095, USA.
authors.forename: U
authors.initials: U
authors.lastname: Kintscher
authors.forename: D
authors.initials: D
authors.lastname: Kon
authors.forename: S
authors.initials: S
authors.lastname: Wakino
authors.forename: S
authors.initials: S
authors.lastname: Goetze
authors.forename: K
authors.initials: K
authors.lastname: Graf
authors.forename: E
authors.initials: E
authors.lastname: Fleck
authors.forename: W A
authors.initials: WA
authors.lastname: Hsueh
authors.forename: R E
authors.initials: RE
authors.lastname: Law
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D002465:Cell Movement / Q000187:drug effects* / Q000502:physiology; D018932:Chemokine CCL2 / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D017292:Doxazosin / Q000494:pharmacology*; D006801:Humans; D020780:Matrix Metalloproteinase 9 / Q000187:drug effects / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000187:drug effects / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D000317:Adrenergic alpha-Antagonists; D018932:Chemokine CCL2; D019715:Tissue Inhibitor of Metalloproteinase-1; D020780:Matrix Metalloproteinase 9; D017292:Doxazosin